<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d571" origId="Linezolid"><sentence id="DrugDDI.d571.s0" origId="s0" text="Monoamine Oxidase Inhibition: Linezolid is a reversible, nonselective inhibitor of monoamine oxidase."><entity id="DrugDDI.d571.s0.e0" origId="s0.p0" charOffset="0-17" type="drug" text="Monoamine Oxidase"/><entity id="DrugDDI.d571.s0.e1" origId="s0.p2" charOffset="30-39" type="drug" text="Linezolid"/><entity id="DrugDDI.d571.s0.e2" origId="s0.p5" charOffset="83-100" type="drug" text="monoamine oxidase"/><pair id="DrugDDI.d571.s0.p0" e1="DrugDDI.d571.s0.e0" e2="DrugDDI.d571.s0.e1" interaction="false"/><pair id="DrugDDI.d571.s0.p1" e1="DrugDDI.d571.s0.e0" e2="DrugDDI.d571.s0.e2" interaction="false"/><pair id="DrugDDI.d571.s0.p2" e1="DrugDDI.d571.s0.e1" e2="DrugDDI.d571.s0.e2" interaction="true"/></sentence><sentence id="DrugDDI.d571.s1" origId="s1" text="Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents."><entity id="DrugDDI.d571.s1.e0" origId="s1.p7" charOffset="11-20" type="drug" text="linezolid"/><entity id="DrugDDI.d571.s1.e1" origId="s1.p13" charOffset="75-94" type="drug" text="serotonergic agents"/><pair id="DrugDDI.d571.s1.p0" e1="DrugDDI.d571.s1.e0" e2="DrugDDI.d571.s1.e1" interaction="true"/></sentence><sentence id="DrugDDI.d571.s2" origId="s2" text="Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents."><entity id="DrugDDI.d571.s2.e0" origId="s2.p14" charOffset="0-17" type="drug" text="Adrenergic Agents"/><entity id="DrugDDI.d571.s2.e1" origId="s2.p18" charOffset="45-50" type="drug" text="ZYVOX"/><entity id="DrugDDI.d571.s2.e2" origId="s2.p22" charOffset="98-106" type="drug" text="pressor"/><entity id="DrugDDI.d571.s2.e3" origId="s2.p25" charOffset="134-156" type="drug" text="sympathomimetic agents"/><entity id="DrugDDI.d571.s2.e4" origId="s2.p26" charOffset="158-169" type="drug" text="vasopressor"/><entity id="DrugDDI.d571.s2.e5" origId="s2.p28" charOffset="173-192" type="drug" text="dopaminergic agents"/><pair id="DrugDDI.d571.s2.p0" e1="DrugDDI.d571.s2.e0" e2="DrugDDI.d571.s2.e1" interaction="false"/><pair id="DrugDDI.d571.s2.p1" e1="DrugDDI.d571.s2.e0" e2="DrugDDI.d571.s2.e2" interaction="false"/><pair id="DrugDDI.d571.s2.p2" e1="DrugDDI.d571.s2.e0" e2="DrugDDI.d571.s2.e3" interaction="false"/><pair id="DrugDDI.d571.s2.p3" e1="DrugDDI.d571.s2.e0" e2="DrugDDI.d571.s2.e4" interaction="false"/><pair id="DrugDDI.d571.s2.p4" e1="DrugDDI.d571.s2.e0" e2="DrugDDI.d571.s2.e5" interaction="false"/><pair id="DrugDDI.d571.s2.p5" e1="DrugDDI.d571.s2.e1" e2="DrugDDI.d571.s2.e2" interaction="false"/><pair id="DrugDDI.d571.s2.p6" e1="DrugDDI.d571.s2.e1" e2="DrugDDI.d571.s2.e3" interaction="true"/><pair id="DrugDDI.d571.s2.p7" e1="DrugDDI.d571.s2.e1" e2="DrugDDI.d571.s2.e4" interaction="false"/><pair id="DrugDDI.d571.s2.p8" e1="DrugDDI.d571.s2.e1" e2="DrugDDI.d571.s2.e5" interaction="true"/><pair id="DrugDDI.d571.s2.p9" e1="DrugDDI.d571.s2.e2" e2="DrugDDI.d571.s2.e3" interaction="false"/><pair id="DrugDDI.d571.s2.p10" e1="DrugDDI.d571.s2.e2" e2="DrugDDI.d571.s2.e4" interaction="false"/><pair id="DrugDDI.d571.s2.p11" e1="DrugDDI.d571.s2.e2" e2="DrugDDI.d571.s2.e5" interaction="false"/><pair id="DrugDDI.d571.s2.p12" e1="DrugDDI.d571.s2.e3" e2="DrugDDI.d571.s2.e4" interaction="false"/><pair id="DrugDDI.d571.s2.p13" e1="DrugDDI.d571.s2.e3" e2="DrugDDI.d571.s2.e5" interaction="false"/><pair id="DrugDDI.d571.s2.p14" e1="DrugDDI.d571.s2.e4" e2="DrugDDI.d571.s2.e5" interaction="false"/></sentence><sentence id="DrugDDI.d571.s3" origId="s3" text="Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied."><entity id="DrugDDI.d571.s3.e0" origId="s3.p29" charOffset="14-19" type="drug" text="drugs"/><entity id="DrugDDI.d571.s3.e1" origId="s3.p30" charOffset="28-47" type="drug" text="phenylpropanolamine"/><entity id="DrugDDI.d571.s3.e2" origId="s3.p32" charOffset="52-67" type="drug" text="pseudoephedrine"/><pair id="DrugDDI.d571.s3.p0" e1="DrugDDI.d571.s3.e0" e2="DrugDDI.d571.s3.e1" interaction="false"/><pair id="DrugDDI.d571.s3.p1" e1="DrugDDI.d571.s3.e0" e2="DrugDDI.d571.s3.e2" interaction="false"/><pair id="DrugDDI.d571.s3.p2" e1="DrugDDI.d571.s3.e1" e2="DrugDDI.d571.s3.e2" interaction="false"/></sentence><sentence id="DrugDDI.d571.s4" origId="s4" text="Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response."><entity id="DrugDDI.d571.s4.e0" origId="s4.p38" charOffset="17-34" type="drug" text="adrenergic agents"/><entity id="DrugDDI.d571.s4.e1" origId="s4.p39" charOffset="44-52" type="drug" text="dopamine"/><entity id="DrugDDI.d571.s4.e2" origId="s4.p41" charOffset="56-67" type="drug" text="epinephrine"/><pair id="DrugDDI.d571.s4.p0" e1="DrugDDI.d571.s4.e0" e2="DrugDDI.d571.s4.e1" interaction="false"/><pair id="DrugDDI.d571.s4.p1" e1="DrugDDI.d571.s4.e0" e2="DrugDDI.d571.s4.e2" interaction="false"/><pair id="DrugDDI.d571.s4.p2" e1="DrugDDI.d571.s4.e1" e2="DrugDDI.d571.s4.e2" interaction="false"/></sentence><sentence id="DrugDDI.d571.s5" origId="s5" text="Serotonergic Agents: Co-administration of linezolid and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies."><entity id="DrugDDI.d571.s5.e0" origId="s5.p50" charOffset="0-19" type="drug" text="Serotonergic Agents"/><entity id="DrugDDI.d571.s5.e1" origId="s5.p53" charOffset="42-51" type="drug" text="linezolid"/><entity id="DrugDDI.d571.s5.e2" origId="s5.p55" charOffset="56-75" type="drug" text="serotonergic agents"/><pair id="DrugDDI.d571.s5.p0" e1="DrugDDI.d571.s5.e0" e2="DrugDDI.d571.s5.e1" interaction="false"/><pair id="DrugDDI.d571.s5.p1" e1="DrugDDI.d571.s5.e0" e2="DrugDDI.d571.s5.e2" interaction="false"/><pair id="DrugDDI.d571.s5.p2" e1="DrugDDI.d571.s5.e1" e2="DrugDDI.d571.s5.e2" interaction="false"/></sentence><sentence id="DrugDDI.d571.s6" origId="s6" text="Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported."><entity id="DrugDDI.d571.s6.e0" origId="s6.p68" charOffset="79-84" type="drug" text="ZYVOX"/><entity id="DrugDDI.d571.s6.e1" origId="s6.p70" charOffset="89-108" type="drug" text="serotonergic agents"/><entity id="DrugDDI.d571.s6.e2" origId="s6.p72" charOffset="120-135" type="drug" text="antidepressants"/><entity id="DrugDDI.d571.s6.e3" origId="s6.p73" charOffset="154-183" type="drug" text="serotonin reuptake inhibitors"/><pair id="DrugDDI.d571.s6.p0" e1="DrugDDI.d571.s6.e0" e2="DrugDDI.d571.s6.e1" interaction="false"/><pair id="DrugDDI.d571.s6.p1" e1="DrugDDI.d571.s6.e0" e2="DrugDDI.d571.s6.e2" interaction="false"/><pair id="DrugDDI.d571.s6.p2" e1="DrugDDI.d571.s6.e0" e2="DrugDDI.d571.s6.e3" interaction="false"/><pair id="DrugDDI.d571.s6.p3" e1="DrugDDI.d571.s6.e1" e2="DrugDDI.d571.s6.e2" interaction="false"/><pair id="DrugDDI.d571.s6.p4" e1="DrugDDI.d571.s6.e1" e2="DrugDDI.d571.s6.e3" interaction="false"/><pair id="DrugDDI.d571.s6.p5" e1="DrugDDI.d571.s6.e2" e2="DrugDDI.d571.s6.e3" interaction="false"/></sentence><sentence id="DrugDDI.d571.s7" origId="s7" text="Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination)."><entity id="DrugDDI.d571.s7.e0" origId="s7.p85" charOffset="30-35" type="drug" text="ZYVOX"/><entity id="DrugDDI.d571.s7.e1" origId="s7.p87" charOffset="52-71" type="drug" text="serotonergic agents"/><pair id="DrugDDI.d571.s7.p0" e1="DrugDDI.d571.s7.e0" e2="DrugDDI.d571.s7.e1" interaction="true"/></sentence><sentence id="DrugDDI.d571.s8" origId="s8" text="If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents)."><entity id="DrugDDI.d571.s8.e0" origId="s8.p117" charOffset="104-109" type="drug" text="ZYVOX"/><entity id="DrugDDI.d571.s8.e1" origId="s8.p119" charOffset="125-144" type="drug" text="serotonergic agents"/><pair id="DrugDDI.d571.s8.p0" e1="DrugDDI.d571.s8.e0" e2="DrugDDI.d571.s8.e1" interaction="false"/></sentence><sentence id="DrugDDI.d571.s9" origId="s9" text="Drug-Laboratory Test Interactions There are no reported drug-laboratory test interactions."/></document>